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Abstract 
Hypertension is a known risk factor for stroke and thus for vascular dementia. 
However, recent large observational studies have suggested that high blood pressure may 
also play a role in Alzheimer's disease. The mechanisms linking hypertension to Alzheimer's 
disease still remain to be fully elucidated but white matter lesions seen on cerebral MRI 
appear to be a good markers of this association. It is not yet clearly established if lowering 
blood pressure reduces the risk of white matter lesions and of dementia, so large trials 
dedicated to this topic are eagerly awaited. These future trials could confirm the hope that, by 
lowering blood pressure, we may dispose of a preventive treatment for dementia. This issue 
is of major importance as the number of cases of dementia is expected to rise sharply in the 
near future in many countries around the world. 
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Introduction 
Dementia is one of the major causes of loss of autonomy and the main reason for the 
institutionalization of the elderly. Epidemiological studies conducted in the last 10 years have 
shown that the prevalence of dementia is close to 5% in the population over 65 years of age. 
These studies have also shown that incidence increases exponentially with age, and as a 
result of the expected shift in population demographics, the incidence and prevalence of 
dementia are expected to increase dramatically over the coming decades. The worldwide 
number of demented patients is projected to grow from 24.3 million in 2001 to 81.1 million in 
2040.1 Significantly, the vast majority of new cases are expected to appear in developed 
countries. For example, the number of demented persons in China and India will increase by 
300% during this period.1 Prevention and management of dementia is therefore a major 
public health challenge in the majority of countries around the world. 
As a general rule, the occurrence of dementia is not a sudden phenomenon. It is the 
final stage of cognitive deterioration, the speed of which varies from one individual to the 
other. But, even in cases where its development is rapid, the process is measured in terms of 
months. Taking into account the life expectancy of individuals at risk, retarding the 
development of dementia for a few months may have important consequences on the 
prevalence of dementia.2 
Such expectations have been raised in recent years with the discovery of a relationship 
between hypertension and dementia. Overall, published studies suggest that high blood 
pressure increases the risk of cognitive decline and dementia, and therefore, that lowering 
blood pressure might reduce this risk. This paper will review the evidence for this, as well as 
raise some of the important questions that still remain unanswered. 
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Hypertension and cognitive decline: evidence from observational 
studies 
What has been known for decades is the direct, causal relationship between high blood 
pressure and the risk of stroke, and therefore the risk of dementia (Figure 1). It is common 
knowledge that large strokes or multiple strokes contribute directly to cognitive decline and to 
the risk of dementia, consequently called vascular dementia. But it is only in the past ten 
years that studies have reported that hypertension may be related to cognitive decline and 
dementia without the occurrence of a stroke. 
Hypertension and stroke-related dementia, a well-established relationship 
 Hospital- and population-based studies have firmly established that dementia is more 
frequent in patients with stroke than in patients without.3-8 Cognitive assessment performed 
three months after stroke revealed that 20 to 30% of patients are demented.7,9,10 In one of the 
largest clinical series of 453 patients who were examined 3 months after their stroke, 26% 
were demented.11. It is estimated that stroke multiplies the risk of dementia by a factor of two 
to five, thus constituting one of the strongest risk factors for dementia.3,5,10,12,13 The strength 
of this association suggests a causal link between stroke and dementia, although numerous 
other factors influence this relationship, some pertaining to the patient – such as age, level of 
education, cognitive level before stroke, white matter lesions on MRI, ApoE4 allele, etc -, and 
others to the stroke itself, mainly its size, severity, and location.  
Interestingly, in the few studies that have implemented a classification of dementia, 
typical vascular dementia represented only 57%11 to 64%7 of all dementias with stroke, thus 
suggesting that a significant proportion of stroke-associated dementias may be classified as 
Alzheimer's disease or mixed dementia. This was confirmed in population-based studies in 
Rochester and New-York, where a 50% to 60% increase in Alzheimer's disease in individuals 
with stroke compared to those without was observed.5,14 These data were interpreted as if 
the occurrence of a stroke may actually simply unmask an ongoing Alzheimer’s disease. This 
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hypothesis was also suggested by studies showing that pre-stroke cognition is altered in 
15% to 20% of patients with a post-stroke dementia.15,16 This interaction between 
neurodegenerative factors or lesions and stroke on the risk of dementia has been 
demonstrated in the Nun study.17 In this autopsy study, small lacunar strokes were found to 
multiply the risk of dementia in individuals meeting the neuropathologic criteria for 
Alzheimer's disease by a factor of 20. 
To summarize, even if the relationship between stroke and dementia is not disputed, it 
appears that the question of the type of dementia is more complex than initially believed. In 
many cases, post-stroke dementia might be related to pre-existing neurodegenerative 
lesions. Conversely, some small and not always clinically noticeable small infarcts may 
precipitate individuals in a clinically conspicuous Alzheimer’s disease. What is not yet 
understood is the extent of these phenomena. If they were not infrequent, the relevance of 
the existing classification of dementia, based on a clear-cut separation of vascular dementia 
and Alzheimer’s disease, would undoubtedly be questioned. 
 
Hypertension and cognitive decline unrelated to a stroke 
Several studies have shown an inverse association between blood pressure and 
cognitive function without the occurence of a stroke (Figure 1). In the Framingham Heart 
Study, Elias et al. examined cognitive function and memory performance as related to initial 
blood pressure measurement over a 12 to 14 year period.18 Among 1,702 subjects, cognitive 
performance was inversely correlated with initial systolic and diastolic blood pressure 
readings: the higher the blood pressure, the lower the cognitive performance. In the 
Honolulu-Asia Aging Study, in which 3,735 Japanese-American male subjects living in 
Hawaii were enrolled, elevated systolic blood pressure at midlife predicted future reduced 
cognitive function. A 10-mmHg increase in systolic blood pressure was associated with a 
significantly increased risk for both intermediate and poor cognitive function. This relationship 
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remained after adjustment for stroke, coronary heart disease, and subclinical 
atherosclerosis.19 Our group conducted a longitudinal study in 1,373 older adults (aged 59-71 
years), the EVA study, to examine whether baseline hypertension and use of 
antihypertensive medication predicted cognitive decline at a 4-year follow-up assessment.20 
We found a relationship between cognitive decline and a history of hypertension (systolic 
blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 95 mmHg), and we also 
discovered that the risk was the highest in patients with untreated hypertension. 
Hypertensive subjects receiving adequate treatment had no increased risk of cognitive 
decline compared with normotensive subjects.20 In another prospective, longitudinal, 
population-based study, it was also found that among 2,068 elderly individuals, subjects 
aged 65 years or older were more likely to make errors on a mental status questionnaire 
when their systolic blood pressure taken 9 years earlier was at least 160 mmHg.21 Some 
studies have not found any association between high blood pressure and cognitive 
function.22-26 This inconsistency has been attributed to the selection of populations 
investigated, differences between the methods used to assess cognitive function, and 
perhaps a misunderstanding of the synchronicity in the development of hypertension and 
cognitive impairment. However, a majority of cross sectional and longitudinal studies have 
found a deleterious effect of high blood pressure on cognition.27,28 
With regard to dementia, several studies have reported a similar association between 
high blood pressure and the risk of dementia. In a longitudinal study in Sweden, a significant 
link was found between the presence of high systolic and diastolic blood pressures and the 
development of dementia 10 to 15 years later.29 Similar findings were reported in other 
studies, such as the Honolulu-Asia Aging Study30, a Finnish study with a 21-year long follow-
up28, and the Kaiser Permanente study31. However, in comparison with the study of simple 
cognitive decline, there is a greater number of studies that show no association between 
dementia and high blood pressure, and some even suggest that dementia is associated with 
low blood pressure.32,33 This could be explained, in full-blown dementia, by the neuronal 
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depopulation of deep brain structures involved in the control of blood pressure or by the 
apathy of severely demented individuals who may have lessened their activity and 
consequently their blood pressure. 
Antihypertensive treatment was sometimes found as being protective in observational 
studies. In a community cohort study of 1,810 persons aged 75 years or older, the 
prevalence of dementia was significantly lower among patients being treated for 
hypertension than among those not taking antihypertensive medications (P < 0.001).34 In The 
Honolulu-Asia Aging Study, early and aggressive blood pressure control lessened the 
likelihood of cognitive impairment in later life.19 Similarly, in the EVA study, hypertensive 
subjects receiving adequate treatment had no increased risk of cognitive decline compared 
with normotensive subjects.20 
 
Randomized trials of blood pressure lowering drugs on the risk of 
dementia 
Prevention of dementia in stroke patients : the PROGRESS study 
Blood pressure lowering therapy with the long-acting ACE inhibitor perindopril 
combined with the diuretic indapamide reduces the risk of post-stroke dementia by one-third 
and the risk of severe cognitive decline by nearly one-half, according to the results from the 
PROGRESS study.35 PROGRESS was a randomized, double-blind, placebo-controlled trial 
that enrolled 6,105 men and women, mean age 64 years, with prior stroke or TIA, from 172 
institutions in 10 countries in Asia, Australia, and Europe. Participants were randomized to 
active treatment (n = 3051) or placebo (n = 3054).36,37 Active treatment was comprised of 
perindopril 4 mg daily for all participants, along with 2.5 mg daily of the diuretic indapamide 
(2 mg in Japan) whether the drug was neither specifically indicated nor contraindicated. The 
main results of PROGRESS38 demonstrated that active treatment with perindopril alone or 
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with indapamide reduced blood pressure by 9/4 mm Hg over 4 years of follow-up and was 
associated with an overall reduction of 28% in the risk of recurrent strokes (the primary 
outcome of the study) compared with placebo (P < .0001 among hypertensive and 
nonhypertensive patients with a history of stroke or transient ischemic attack [TIA]). Active 
treatment also reduced the risk of total major vascular events by 26%. Combination therapy 
with perindopril plus indapamide reduced blood pressure by 12/5 mm Hg and stroke risk by 
43%. One of the secondary outcomes of PROGRESS was dementia and severe cognitive 
decline. During the follow-up period of 4 years, dementia (diagnosed according to DSM-IV 
criteria) and severe cognitive decline (a drop of ≥ 3 points in the Mini Mental State 
Examination [MMSE]) were assessed. Median MMSE score at baseline was 29 (range, 27-
30); a large proportion of patients (41%) had good cognitive function (MMSE = 30), but 16% 
had cognitive impairment (MMSE < 26). Over 25% of patients screened positive for dementia 
(768 and 812 in the active treatment and placebo groups, respectively). After independent 
assessment by an expert in dementia, 410 patients were identified as having dementia 
(equivalent to an incidence of 17 per 1,000 patient years), of whom 108 had a dementia 
preceded by a stroke. Cognitive decline was identified in 610 patients (incidence of 25 per 
1000 patient years), of whom 134 had a previous stroke. Overall, there was a nonsignificant 
12% (range, -8% to -28%) reduction in the risk of dementia in the active treatment group. 
Evaluation within the two dementia subgroups (with or without prior stroke), however, 
showed a significant reduction of 34% (P = .03) in the risk of dementia with active treatment 
in patients with prior stroke and a 1% reduction in patients without prior stroke. A similar 
pattern was observed for cognitive decline, with an overall risk reduction of 19% with active 
treatment overall, but a significant risk reduction of 45% (P < .001) with active treatment in 
patients with prior stroke and a 9% reduction in patients without stroke. Combination therapy 
was more effective in reducing the risk of dementia (23%) than monotherapy (-8%). In 
patients with no cognitive impairment at baseline (84%), active treatment reduced the risk of 
dementia by 31%, but there was no effect in patients with cognitive impairment at baseline (-
3%). Among the patients without cognitive impairment at baseline, a 50% reduction in the 
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risk of dementia was observed in those with prior stroke, compared with a 16% reduction in 
those without stroke.  
Trials in hypertensive patients without stroke 
Four large-scale randomized controlled trials using blood pressure lowering agents 
have reported the effects of treatment on the risk of dementia or measures of cognitive 
function.39-42 While three trials identified no clear effect of the treatment under study on the 
risk of dementia39,42 or on cognitive function,40,42 one reported a significant benefit from 
treatment on the risk of dementia.41  
In the Systolic Hypertension in the Elderly Program (SHEP),39 active treatment had no 
discernible effect on the incidence of dementia. Similarly, in the UK Medical Research 
Council’s trial in older hypertensive patients, there was no apparent effect of treatment on 
any other measure of cognitive impairment.40 However, in the Systolic Hypertension in 
Europe Trial (Syst-Eur), the incidence of dementia among those assigned active treatment 
was about half that of patients assigned placebo, although there was no effect on MMSE 
scores in either group.41 These inconsistencies may be due to random error, since the 
numbers of cases of dementia reported in the previous studies were small (in total, there 
were 113 cases of confirmed dementia in the earlier studies compared with 410 in the 
present study), or to differences in the populations studied. A recent analysis of data from the 
SHEP study suggests that differential drop-out rates in active treatment and placebo groups 
in that study may have introduced a bias towards the null in the assessment of treatment 
effects on dementia.43 
 The most exciting data with regard to the prevention of dementia by lowering blood 
pressure have come from the Syst-Eur trial.41,44 The Syst-Eur trial was a double-blind, 
placebo-controlled trial of nitrendipine, a calcium antagonist, with the addition of enalapril, 
hydrochlorothiazide, or both, titrated or combined as needed to reduce systolic blood 
pressure by at least 20 mmHg so as to reach a target of <150 mmHg in over 4,000 patients 
9 
H
AL author m
anuscript    inserm
-00150111, version 1
aged over 60 years. Syst-Eur included a dementia sub-study on a subset of 2,418 patients 
(1,180 in the placebo group and 1,238 in the active-treatment group). At the end of the trial, 
which was stopped prematurely after a median follow-up of 2 years because the preplanned 
interim analyses demonstrated a significant benefit for stroke, 1,861 patients remained on 
double-blind treatment; 60% received nitrendipine alone, 32% received nitrendipine plus 
enalapril, and 15% received these two drugs plus hydrochlorothiazide. Dementia was 
diagnosed in 21 cases in the placebo group and in 11 cases in the active treatment group, 
resulting in a 50% reduction in the incidence of dementia in the active arm. Interestingly, the 
majority of cases prevented were of Alzheimer’s disease. This remarkable finding should, 
however, be interpreted with caution because of the small number of outcome events. As 
result, the possible impact of blood pressure lowering can extend from having no effect to a 
massive 76% reduction in the risk of dementia. Moreover, the large number of participants 
who were lost to follow-up further undermines the validity of the study. 
In another randomized trial, the Study on Cognition and Prognosis in the Elderly 
(SCOPE), no treatment effect on cognition was observed.42,45 SCOPE was a prospective, 
double-blind, randomized, parallel-group study conducted from 1997 to 2002, in which 4,964 
patients aged 70 to 89 years, with SBP 160-179 mm Hg and/or DBP 90-99 mm Hg 
(untreated or thiazide-treated) and MMSE test score ≥ 24, were assigned to receive 
candesartan or placebo with open-label active antihypertensive therapy added if necessary. 
No significant difference was observed in mean final MMSE score between the candesartan 
group (final score 28.0) and the control group (final score 27.9) (P = .20), and the proportion 
of patients who had a significant cognitive decline or who developed dementia was not 
different in the 2 treatment groups.42 However, due to ethical concerns, this study was finally 
redesigned to compare effects between the candesartan-based treatment and the usual 
antihypertensive therapy regimens and, as result, the reduction of blood pressure was limited 
(Table). 
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In summary, there are still very few large trials that have assessed the prevention of 
dementia by blood pressure lowering drugs (Table). PROGRESS is the only study that has 
assessed the risk of dementia in patients with stroke. It reports a reduction of the risk of post-
stroke dementia and no clear effect on the risk of dementia without stroke.35 The most 
convincing to date in non-stroke patients, the Syst-Eur trial, is hampered by the relatively 
small number of cases. In an open extension of the follow-up the results of the main study 
were confirmed with a doubling of the number of cases.46 However, special caution is 
needed to interpret these results because of the limitations and the potential biases of an 
open follow-up. A large and specifically-designed trial is therefore needed to confirm and to 
quantify the reduction of the risk of dementia by blood pressure lowering drugs in 
hypertensive subjects.  
 
Mechanisms of the relationship between hypertension and 
cognition when there is no stroke : the white matter lesions 
hypothesis 
The mechanisms by which high blood pressure can operate at the cerebral level are 
widely unknown. Recently, the development of cerebral imaging and more particularly of MRI 
(Magnetic resonance imaging) has shown that silent strokes, and more broadly, white matter 
lesions (WML) are common, in particular in patients with hypertension and in the elderly 
(Figure 2).  
WML: definition and risk factors 
WML are areas of high signal on T2-weighted images located in the cerebral white 
matter, and among them, silent strokes may be singled out by their low signal on T1-
weighted images. These lesions share the same risk factors as stroke, mainly age47-53 and 
hypertension54-58. Some studies have shown that a sustained high blood pressure level 
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increases the risk of WML, suggesting that there was a dose-response relationship.56,57 The 
level of blood pressure also seems to play a role, the highest blood pressure values being 
associated with the higher grades of WML.59 This aspect of dose-response in terms of 
duration and level of exposure are important arguments to suggest that the relationship 
between high blood pressure and WML may be causal, as it is for stroke. 
The mechanisms leading to WML are not yet fully understood but degeneration of 
small caliber arteries (arteriosclerosis) has been consistently found,60-62 as well as a reduced 
cerebral blood flow,63-66 which are both known consequences of high blood pressure on the 
brain.67-69 Therefore, it is generally assumed that WML are a marker of a chronic state of 
cerebral ischemia in hypertensive patients. 
Consequences of WML 
One general hypothesis is that the accumulation of lesions in the white matter can lead 
to a subsequent cognitive deterioration by disconnection of cortico-subcortical pathways. 
Several studies have indeed shown that WML are associated with cognitive 
impairment47,52,53,59,70-72 and with dementia73-75 (Figure 1). Several aspects are however still 
poorly understood: What is the relative importance of the location, the type, and the extent of 
WML on the risk of cognitive impairment? Are there major effect modifiers on this 
relationship, such as the apolipoprotein E polymorphism and education level? Are WML 
associated with cortical atrophy? If yes, as suggested by some studies,76-78 what is the 
relative importance of both on the risk of cognitive impairment? Some of these questions 
have already been addressed, though very often with small series of selected patients. 
Further, the evaluation of WML is highly variable across studies and no clear consensus has 
yet emerged to date. 
WML have been also found to be associated with gait disturbances and a higher risk of 
falls,79-83 symptoms resembling Parkinson’s disease,84-86 as well as a higher risk of stroke87,88 
and depression89-93. It is therefore not an overstatement to say that WML – at least when 
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their load is elevated – are guilty of accelerating aging of the brain. Trying to control their 
aggravation is therefore an important goal. 
 
Preventing the evolution of WML: the PROGRESS-MRI study 
This was a substudy of the PROGRESS trial just described above. In this substudy, we 
analyzed data gathered on 192 people (average age 60) recruited in ten centers in France. 
Each participant had a brain MRI at baseline which was repeated after an average follow up 
of 36 months. At baseline, a neuroradiologist examined each scan and determined that 42 
percent of participants had no WML; 26 percent had mild WML, 13 percent had moderate 
WML and 19 percent had severe WML. Eighty-nine patients were in the active treatment 
arm, and 103 were under placebo. About half of the subjects were already being treated for 
high blood pressure. At the time of the second MRI, blood pressure had decreased at an 
average of 11.2 mm Hg systolic and 4.3 mm Hg diastolic. In order to limit the variability 
between the two exams attributable to the MRI technique (position of the head of the patient, 
different slicing, etc.), we performed an automatic registration and segmentation of both MRI 
exams after their storage in an Object Oriented Relational Database. By doing so, we made 
both exams as comparable as possible, and an independent observer, blinded to the data 
and the order of the MRI exams, would be able to compare them precisely and detect and 
measure any new lesion. Overall, the risk of new WML was reduced by 43 percent in the 
treatment group compared to the placebo group, although the difference did not reach 
significance (P=0.10). The volume of new areas of WML in the treatment group was one-fifth 
of that in the untreated group (0.4 cubic millimeters versus 2 cubic millimeters) (P = 0.047). 
The most striking difference was noted in the 27 patients who already had severe WML at 
the first MRI. In this group, no new areas of abnormality developed in those in the treatment 
group, compared with an average of 7.6 cubic millimeters of new WML in patients on placebo 
(P = 0.001). 
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This study showed, for the first time, that it is possible to limit the development of WML 
by lowering blood pressure even though the number of subject was rather small. As result of 
this low power, there was no sufficient power to study simultaneously the impact of treatment 
on cognition in this sample. Further studies are needed to confirm these results in larger and 
independent samples. Also, studies should be performed in patients who do not have a past 
history of cerebrovascular disease. 
 
Tentative conclusions and future prospects 
There is no doubt that high blood pressure is associated with cognitive deterioration 
and dementia independently of the occurrence of a stroke. Conflicting results came in part 
from the various ways of testing cognition and defining cognitive decline, and the lack of 
precisely diagnosing dementia in its early stage. Another, and yet unsolved, issue is the 
modification of this relationship with age. It is likely that the risk of cognitive deterioration 
related to high blood pressure decreases with increasing age. A similar modification of the 
risk with age is observed in the relationship between hypertension and stroke. Further, there 
appears to be spontaneous lowering of blood pressure in the stage of advanced dementia, 
probably through neuronal depopulation in the centers regulating blood pressure, which 
renders the relationship even more complex. Finally, the true relative risk of dementia 
associated with hypertension is probably relatively modest compared to other stronger risk 
factors for dementia like age, education, and the apoE polymorphism. Therefore, some 
degree of fluctuation is not unexpected when estimating this risk and some of the 
controversial results could be thus explained. 
Despite these difficulties, clarifying this relationship remains of major importance. With 
the ageing of our societies, we are facing an epidemic of dementia for which we have no 
curative or preventive treatment. In this context, even a modest reduction of the risk would 
have important consequences. Moreover, even if high blood pressure is associated with a 
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moderate relative risk of dementia, its very high prevalence means that the risk of dementia 
attributable to high blood pressure may be high and that an improved control of hypertension 
may translate into a dramatic reduction of the number of cases of dementia.94 
Several questions remain however unanswered:  
What is the true magnitude of the relationship? The data are still insufficient and we 
definitively need more population-based studies in the elderly in order to accurately estimate 
the risk of dementia attributable to high blood pressure and other vascular factors. Some of 
the existing large population-based studies in this domain should also combine their efforts in 
a view of producing an exact measure of this risk.  
Is it possible to identify individuals or groups at high risk? It is likely that the effect of 
high blood pressure on the brain varies dramatically between individuals, even among 
hypertensive patients. Those at high risk of hypertension-related cognitive decline or 
dementia would benefit the most from an accurate control of their hypertension. Again, these 
high risk groups can be properly identified only in large observational studies with a long 
follow-up.  
Are WML an appropriate marker of the bad tolerance of high blood pressure by the 
brain? The answer is most likely positive but several issues on the true mechanisms linking 
WML to cognition remain unresolved, in particular regarding their characteristics : location, 
size, signal intensity, etc. In addition, what is not well understood, too, is the natural history of 
WML. Results from a few studies suggest that some patients have a rapid increase of their 
WML load and that they would be those who have a higher risk of severe cognitive decline, 
but this remain to be confirmed. 
These questions are important and must be answered to improve our understanding of 
the relationship between hypertension and dementia. However, it is also sustainable to state 
that we have enough data at hand to set up a clinical trial on the reduction of the risk of 
dementia by lowering blood pressure. This trial, specifically designed to study dementia, 
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should be very large so as to produce a significant number of cases with the longest follow-
up as possible. Among some other important variables, the investigators of this trial will have 
to choose the type of patients that should be included : old-old patients are more exposed to 
a short-term risk of dementia but blood pressure lowering drugs might be less effective in 
these patients than in young-old patients who are, in turn, less prone to dementia. 
Demonstrating a treatment effect in youngest hypertensives would require a much larger 
number of patients or a longer follow-up. The choice of the type of drug could also be 
important as it is not yet known if the protective effect observed is uniquely due to the 
lowering of blood pressure or if there is a class effect. A meta-analysis95 suggests that 
calcium antagonists are more effective than other drugs in reducing the risk of stroke in 
hypertensive patients. Could this apparent class effect also apply on the risk of dementia is 
an open question. Finally, an important decision is whether to perform or not MRI's on part of 
or on the entire sample. The data from MRI exams would be of great value in confirming the 
impact of the blood pressure lowering drug on the brain and in understanding the variability 
of this impact across categories of patients. 
Epidemiology of dementia and cognitive deterioration has now completed its first phase 
which begun in the early nineties and provided extensive descriptive data. Given the growing 
epidemiological and clinical evidence for the implication of vascular factors on the risk of 
dementia, the identification and control of these factors in middle-aged and elderly individuals 
may represent an important approach for decreasing the incidence of dementia. This could 
be demonstrated properly only through large randomized trials. One can expect that, as for 
coronary heart diseases, the second phase of the epidemiology of dementia will be devoted 
to such trials.  
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 Table. Main randomized trials on antihypertensive drugs and the risk of dementia 
 
Study 
Sample 
size 
SBP/DBP 
difference (active 
vs. placebo) 
Drug tested 
Duration of 
follow up 
Reduction of the 
risk of dementia 
P value 
SHEP39 4736 -12 / 4 mmHg BB ± diuretic 4.5 years 16% NS 
SYST-EUR41 2418 - 8.3 / 3.8 mmHg CCB ± ACE ± 
diuretic 
2 years 50% (0-76%) 0.05 
PROGRESS35 6105 - 9 / 4 mmHG ACE ± diuretic 4 years All dementia : 
12% (-8-28%) 
Dementia with 
recurrent stroke : 
34% (3-55%) 
 
NS 
 
0.03 
SCOPE42 4964 - 3.2 / 1.6 mmHg ARB 4 years 7% NS 
BB : Beta Blocker ; CCB : Calcium Channel Blocker ; ACE : Angiotensin Converting Enzyme Inhibitor ; ARB : Angiotensin 
II type1 Receptor Blocker ; NS : non significant 
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Figure 1. Diagram of the consequences of hypertension on the brain 
Legend : WML : white matter lesions 
 
Figure 2. White matter lesions on cerebral MRI 
Legend : Cerebral MRI of two women 67 years of age without (on the left) and with (on the 
right) hypertension. Participant with hypertension had several deep and periventricular white 
matter lesions (arrows). 
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